Route of administration for antibiotics with high oral bioavailability by Smith, Michael J et al.













Ann & Robert H. Lurie Children’s Hospital
Matthew P. Kronman
University of Washington - Seattle Campus
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Smith, Michael J.; Thurm, Cary; Shah, Samir S.; Patel, Sameer J.; Kronman, Matthew P.; Gerber, Jeffrey S.; Courter, Joshua D.; Lee,
Brian R.; Newland, Jason G.; and Hersh, Adam L., ,"Route of administration for antibiotics with high oral bioavailability." Infection
Control & Hospital Epidemiology.40,02. 248-249. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/7510
Authors
Michael J. Smith, Cary Thurm, Samir S. Shah, Sameer J. Patel, Matthew P. Kronman, Jeffrey S. Gerber, Joshua
D. Courter, Brian R. Lee, Jason G. Newland, and Adam L. Hersh
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/7510
Infection Control & Hospital Epidemiology (2019), 40, 248–249
doi:10.1017/ice.2018.329
Research Brief
Route of administration for antibiotics with high oral
bioavailability
Michael J. Smith MD, MSCE1, Cary Thurm PhD2, Samir S. Shah MD, MSCE3, Sameer J. Patel MD4,
Matthew P. Kronman MD, MSCE5, Jeffrey S. Gerber MD, PhD6, Joshua D. Courter PharmD7,
Brian R. Lee MPH, PhD8, Jason G. Newland MD, MEd9 and Adam L. Hersh MD, PhD10
1Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina, 2Children’s Hospital Association, Overland Park, Kansas,
3Divisions of Hospital Medicine and Infectious Diseases, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine,
Cincinnati, Ohio, 4Division of Pediatric Infectious Disease, Ann & Robert H. Lurie Children’s Hospital, Chicago, Illinois, 5Division of Infectious Diseases, Seattle
Children’s Hospital, University of Washington School of Medicine, Seattle, Washington, 6Division of Infectious Diseases, Children’s Hospital of Philadelphia,
Philadelphia, Pennsylvania, 7Division of Pharmacy, Cincinnati Children’s Hospital Medical, Cincinnati, Ohio, 8Division of Infectious Diseases, Children’s Mercy
Hospital-Kansas City, Kansas City, Missouri, 9Division of Pediatric Infectious Diseases, Washington University School of Medicine, St Louis, Missouri and
10Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Utah, Salt Lake City, Utah
(Received 12 June 2018; accepted 16 September 2018)
National stewardship guidelines recommend that hospitals develop
interventions to increase use of oral antibiotics.1 Transition from
intravenous to oral route of administration for antibiotics with high
oral bioavailability (HOB) is a simple intervention shown to
decrease cost and length of hospitalization. We sought to determine
the prevalence of use and route of administration of HOB anti-
biotics at children’s hospitals to determine how frequently intra-
venous to oral switch might be feasible and to quantify potential
cost savings of this strategy in hospitalized children.
Methods
We used 2015 data from the Pediatric Health Information System
(PHIS), an administrative and clinical database maintained by the
Children’s Hospital Association.2 Patients were included if they
were potentially eligible for intravenous to oral switch as defined
by (1) receipt of an HOB antibiotic, (2) receipt of ≥1 nonantibiotic
oral medication on the same day as the antibiotic, and (3) hospital stay
>2 days. The HOB antibiotics included clindamycin, metronidazole,
ciprofloxacin, levofloxacin, doxycycline, linezolid and rifampin, all of
which have ≥80% oral bioavailability.3 Antimicrobials typically used
for prophylaxis (azithromycin, trimethoprim-sulfamethoxazole, and
azoles) were excluded because they are usually given orally and it is
difficult to distinguish treatment from prophylaxis using PHIS data.
Days of therapy (DOT) for each drug were reported overall
and stratified by route and hospital. Oral administration of HOB
antibiotics was reported using 2 metrics: (1) the percentage of all
HOB antibiotic DOT that were administered orally (% PO DOT)
and (2) the percentage of all patients receiving HOB antibiotics
who received doses orally, either completely or in combination
with intravenous therapy. If children received antibiotic doses via
both routes on the same day it was counted as an oral DOT.
Specific diagnoses were identified using All Patient Refined
Diagnosis Related Groups (APR-DRGs).
Antibiotic costs were estimated using institution-specific cost-
to-charge ratios. Maximal cost-savings were estimated using the
same institution-specific cost-to-charge ratios under the alternate
case of administering all doses of HOB antibiotics orally.
Results
Data from 48 freestanding children’s hospitals were included:
38,933 children received 221,535 DOT of HOB antibiotics and at
least 1 nonantibiotic oral medication, accounting for ~17% of all
PHIS antibiotic use. Overall, 35.8% of all HOB DOT were
administered orally, ranging from 21.3% to 63.8% across institu-
tions. Clindamycin was the most commonly prescribed HOB
antibiotic, accounting for nearly half of all HOB DOT (Table 1).
However, it had the lowest percentage of oral DOT (21.7%) and the
highest percentage (63.0%) of intravenous-only receipt. Cellulitis
was the most common diagnosis associated with clindamycin use,
for which 27.6% of DOT were oral. Other common diagnoses
included pneumonia (26% oral DOT) and musculoskeletal infec-
tions (16% oral DOT).
The HOB antibiotics most likely to be prescribed orally were
rifampin (80.5% of all DOT) and doxycycline (70.8% of all DOT).
Fluoroquinolones were administered orally for only half of all
DOT. However, there was significant variation in the proportion
of oral fluoroquinolone use across institutions, ranging from
27.0% to 98.3% for ciprofloxacin and from 0 to 100% for levo-
floxacin. Similarly, less than one-third of linezolid DOT were
administered orally, ranging from 0 to 100% across institutions.
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The total hospital cost for all HOB antibiotics administered
during the study period was $11,662,963. The estimated cost had
all doses been administered orally was $5,891,137.
Discussion
Only 36% of HOB antibiotic DOT were administered orally in
this cohort of children receiving other oral medications. These
data suggest that intravenous to oral switch programs should be
prioritized in children’s hospitals. Clindamycin should be a priority
target for such programs because it is both commonly used and often
administered intravenously. It is well-documented that intravenous to
oral switch is safe and effective for children with osteomyelitis4,5 and
complicated pneumonia,6 2 common indications for clindamycin.
However, in this cohort, children with these diagnoses were more
likely to be treated with intravenous clindamycin.
Intravenous to oral switch programs would be cost saving in
pediatrics. We estimated a nearly 50% decrease in drug cost alone.
Although this represents the maximum potential savings in direct
drug costs, it does not account for additional cost savings due to
drug administration, shorter hospital stays, avoidance of outpatient
parenteral antibiotic therapy and catheter-associated infections.
The reasons for underutilization of oral administration are
uncertain. Some clinicians and parents may have the perception
that intravenous antibiotics are more effective7 or that insurance
companies mandate intravenous therapy for reimbursement of
hospitalization. Future studies should focus on differences in
clinical outcomes between children who received HOB antibiotics
via oral as compared to intravenous routes.
This analysis has several limitations. We utilized adminis-
trative data to identify children eligible for oral conversion.
Although this approach has been used in other studies,8 we could
not account for patient factors such as severity of illness or
intolerance of oral antibiotics, though inclusion in this cohort
required receipt of another oral medication. We did not exclude
diagnoses that mandate intravenous therapy such as endovas-
cular or central nervous system infections. However, it is unli-
kely that differences in the prevalence of these infections would
explain more than a minority of the variation in use of oral
antibiotic across hospitals. Finally, because PHIS only includes
data from freestanding children’s hospitals, most of which have
formal ASPs,9 these results may not be generalizable to other
settings.
In conclusion, we observed frequent intravenous administra-
tion of HOB antibiotics at children’s hospitals. Intravenous to oral
conversion programs, with a focus on clindamycin and fluor-
oquinolones, are potential high-impact targets for antimicrobial
stewardship.
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Table 1. Prevalence of High Oral Bioavailability Antibiotic Use and Proportion of Oral Administration
Route of Antibiotic Administration, % Patients
Drug DOT % PO DOT Overall Min % Max % No. of Patients PO Only IV Only Both
Clindamycin 102,628 21.7 4.7 65.7 21,956 9.1 63.0 27.9
Metronidazole 52,478 38.4 12.3 71.7 10,270 32.1 53.0 15.0
Ciprofloxacin 26,125 55.1 27.0 98.3 5,480 53.9 29.8 16.3
Levofloxacin 14,341 50.4 0.0 100.0 2,496 48.6 34.6 16.8
Linezolid 9,820 30.8 0.0 100.0 1,644 32.3 54.3 13.4
Doxycycline 8,189 70.8 29.6 98.3 1,522 61.2 20.8 17.9
Rifampin 7,954 80.5 0.0 100.0 998 75.3 12.8 11.9
Overall 221,535 35.8 21.3 63.8 38,993 22.9 50.8 26.3
Note. PO, per oral; DOT, days of therapy; Min %, % PO DOT at hospital with lowest % PO DOT for each drug; Max %, % PO DOT at hospital with highest % PO DOT for each drug; IV,
intravenous.
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